Humacyte (HUMA) Q1 2026 earnings summary

Executive summary

• Symvess commercial launch advanced in the U.S. and internationally, with Q1 2026 sales rising to $0.5 million from $0.1 million year-over-year, following FDA approval in December 2024 and commercial shipments beginning March 2025.

• Expanded leadership team with new Chief Commercial Officer and Chief Surgical Officer to drive commercialization and clinical strategy.

• Secured a $1.475 million purchase commitment from Saudi Arabia and submitted a marketing authorization application for Symvess in Israel.

• Workforce restructuring in May 2026 reduced headcount by 25%, targeting $14.3 million in net savings for the remainder of 2026, with a one-time charge of $0.8 million.

• Progressed V012 phase III trial for ATEV in dialysis access, with interim results expected June 2026; first-in-human CTEV CABG study planned for second half of 2026.

Financial highlights

• Symvess product revenue reached $0.5 million (29 units) in Q1 2026, up from $0.1 million (5 units) in Q1 2025; contract revenue declined to $2,000 from $0.4 million.

• Cost of goods sold increased to $2 million, including a $1.6 million inventory reserve and overhead for unused capacity.

• R&D expenses rose to $19.5 million from $15.4 million, mainly due to CTEV production and process improvements.

• Net loss was $17.6 million, compared to net income of $39.1 million in Q1 2025, primarily due to lower non-cash income from contingent earn-out liability.

• Cash, equivalents, and restricted cash totaled $48.9 million as of March 31, 2026; working capital was $47.4 million.

Outlook and guidance

• Too early to provide 2026 revenue guidance; expecting to offer guidance by year-end.

• Anticipates accelerating revenues in 2026 due to revamped commercial strategy and expanded sales team.

• Plans to submit a supplemental BLA for dialysis indication in the second half of 2026, with potential FDA decision by mid-2027 if accelerated review is granted.

• Expects $14.3 million in operating expense savings for the remainder of 2026 from restructuring.

• Substantial doubt exists about the ability to continue as a going concern beyond one year without additional capital or increased sales; plans to seek additional funding.